
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
The European Medicines Agency’s Management Board met to discuss EMA’s future premises in Amsterdam. With the anticipated move in March of 2019, the EMA needs to have a designated location to operate, but with this discussion it has been seen that the building will not be completed in time and they will have to settle upon a temporary premises.
Read the full release






